Clinical Qualification of Subcutaneous Injection Devices for Monoclonal Antibodies

Area of Science:

• Biologics and Biotechnology
• Pharmacokinetics and Drug Delivery
• Medical Device Development

Background:

• Subcutaneous autoinjectors enhance drug self-administration, patient compliance, and dosing accuracy compared to manual injections.
• Technical requirements for new molecules often delay autoinjector availability, necessitating manual injections and subsequent pharmacokinetic comparability studies.
• Current development pathways require extensive molecule-specific studies to validate autoinjector use.

Purpose of the Study:

• To propose and evaluate a Molecule-Independent Device Bridging Approach (MIDBA) for streamlining autoinjector validation.
• To eliminate the need for dedicated pharmacokinetic comparability studies for each new monoclonal antibody (mAb) using a validated autoinjector platform.
• To support efficient transition from manual to automated subcutaneous injections for biotherapeutics.

Main Methods:

• A narrative review of clinical data from 29 pharmacokinetic comparability studies was conducted.
• Analyzed pharmacokinetic and tolerability profiles from studies involving both manual and automated injections.
• Evaluated the applicability of the MIDBA by comparing PK data from different mAbs with dosing volumes up to 2 mL.

Main Results:

• Pharmacokinetic and tolerability profiles were comparable between manual and automated injections, irrespective of the molecule or device.
• The MIDBA demonstrated applicability as a streamlined pathway for autoinjector validation.
• The slow absorption rates of mAbs following subcutaneous injection are primarily influenced by tissue residence time and lymphatic drainage, not injection method specifics.

Conclusions:

• The MIDBA provides a novel and efficient framework for biotherapeutic autoinjector validation.
• This approach eliminates the necessity for molecule-specific pharmacokinetic studies, reducing development time and cost.
• The findings support the broader adoption of autoinjectors for subcutaneous drug delivery.